Concurrent Chemotherapy and Intensity-modulated Radiation Therapy for Anal Carcinoma - Clinical Outcomes in a Large National Cancer Institute-designated Integrated Cancer Centre Network

Clinical Oncology

Volumn 24, Issue 6, 2012, Pages 424-431

  DeFoe, S G ^a   Beriwal, S ^a   Jones, H ^a   Rakfal, S ^a   Heron, D E ^a   Kabolizadeh, P ^a   Smith, R P ^a   Lalonde, R ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b D3 Radiation Planning   (United States)

Author keywords

Acute toxicities; Anal cancer; Cisplatin; Concurrent chemoradiotherapy; Intensity modulated radiation therapy; Mitomycin

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; LEVOLEUCOVORIN; MITOMYCIN;

ADULT; AGED; ANEMIA; ANUS CANCER; ANUS CARCINOMA; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; COLOSTOMY; COMMUNITY CARE; CONTROLLED STUDY; DISTANT FAILURE FREE SURVIVAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CHEMORADIOTHERAPY; CISPLATIN; COMMUNITY HEALTH CENTERS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NATIONAL CANCER INSTITUTE (U.S.); RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84863831466     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.09.014     Document Type: Article

References (17)

1. Ajani J., Winters K.A., Gunderson L.L., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, amd radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008, 299:1914-1921.
2. Bartelink H., Roelofsen F., Eschwege F., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer. Results of a phase III randomized trial of European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997, 15:2040-2049.
3. Flam M., Madhu J., Pajak T.F., et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996, 14:2527-2539.
4. UKCCCR.Anal Cancer Working Party, UK Co-ordinating Committee on Cancer Research: Epidermoid Anal Cancer Results from the UKCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996, 348:1049-1054.
5. Milano M., Jani A.B., Farrey K.J., Heimann R., Chmura S.J. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. IJROBP 2005, 63:354-361.
6. Halperin E.C., Perez C.A., Brady L.W. Priniciples and practice of radiation oncology 2008, Lippincott Williams & Wilkins, Philadelphia. 5th ed.
7. Brixey C., Roeske J.C., Lujan A.E., Yamada S.D., Rotmensch J., Mundt A.J. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. IJROBP 2002, 54:1388-1396.
8. Graf R., Wust P., Hildebrandt B., et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 2003, 65:14-22.
9. Weber D., Kurthz J.M., Allal A.S., Weber D.C., Kurtz J.M., Allal A.S. The impact of gap duration on local control of anal cancer treated by split-course radiotherapy and concomitant chemotherapy. IJROBP 2001, 50:675-680.
10. Beriwal S., Gan G.N., Heron D.E., et al. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. IJROBP 2007, 68:166-171.
11. Beriwal S., Heron D.E., Kim H., et al. Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. IJROBP 2006, 64:1395-1400.
12. Beriwal S., Jain S.K., Heron D.E., et al. Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol 2006, 102:195-199.
13. Salama J., Mell L.K., Schomas D.A., et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal cancer patients: a multicenter experience. J Clin Oncol 2007, 25:4581-4586.
14. Kachnic L., Winter K., Myerson R., et al. RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-c for reduction of acute morbidity in carcinoma of the anal canal [Abstract]. IJROBP 2009, 75(Suppl. 5).
15. Kachnic L.A., Winter K.A., Myerson R.J., et al. Two-year outcomes of RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal [Abstract]. J Clin Oncol 2011, 29(Suppl. 4).
16. John M., Pajak T., Flam M., et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08 [Abstract]. Cancer J Sci Am 1996, 2:205-211.
17. Mell L., Schomas D.A., Salama J.K., et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. IJROBP 2008, 70:1431-1437.